



Attorney Docket No.: 6246.200-US

PATENT

1632
#7
IDS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: P. Serup et al

Serial No.: 10/090,011

Group Art Unit: To be assigned

Filed: February 26, 2002

Examiner: To be assigned

Confirmation No: 3868

For: Methods for Generating Insulin-Secreting Cells Suitable For Transplantation

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231

on December 10, 2002.

Rashida Haji
(name of person mailing paper)

Rashida Haji
(signature of person mailing paper)

RECEIVED
DEC 16 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: P. Serup et al

Application No.: 10/090,011

Group Art Unit: To be assigned

Filed: February 26, 2002

Examiner: To be assigned

Confirmation No: 3868

For: Methods for Generating Insulin-Secreting Cells Suitable For Transplantation

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

RECEIVED
DEC 16 2002
TECH CENTER 1600/2900

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed. The references are as follows:


1. WO 00 59936 A
2. US Patent 5,695,995
3. Jensen et al, Diabetes, NY, Vol. 49, No. 2, Pages 163-176, (2000)
4. Grapin - Botton et al, Genes & Development, Vol.15, Pages 444-454, (2001).

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **before** the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,

Date: December 10, 2002


Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800



23650

PATENT TRADEMARK OFFICE

